Tag Investor Alert

Piramal Pharma Ltd
Piramal Pharma Ltd. surges 3.8%—key Insights and Growth Outlook

Business and Industry Overview: 

Piramal Pharma Limited (PPL) is a global pharmaceutical company. It develops, manufactures, and sells medicines and healthcare products. The company has 17 factories in different countries. It sells its products in over 100 countries. PPL operates in three main areas. Piramal Pharma Solutions (PPS) helps other companies make medicines. Many companies do not have their own factories. They ask PPL to develop and manufacture medicines for them. PPL helps in research, testing, and production. This allows new medicines to reach people faster. Piramal Critical Care (PCC) makes medicines used in hospitals. These include painkillers, anesthesia drugs, and medicines for serious infections. Doctors use these medicines for surgeries and emergency treatments. Hospitals rely on them for intensive care and life-saving procedures. India Consumer Healthcare makes everyday health products. These products can be bought in stores without a prescription. Some popular products include Saridon (for headaches), Lacto Calamine (for skincare), and Polycrol (for digestion problems). Many people in India use these products in their daily lives. PPL has important partnerships and investments. It works with AbbVie Inc., a well-known pharmaceutical company. Together, they have a joint venture called AbbVie Therapeutics India Private Limited. This company makes medicines for eye diseases. It is a leader in ophthalmology in India. PPL has also invested in Yapan Bio Private Limited. This company works on biotechnology and develops new medicines. In October 2020, The Carlyle Group invested in PPL. They bought 20% of the company. This helped PPL expand its research, production, and market reach. PPL is part of the Piramal Group. This group also works in finance and real estate. It operates in over 30 countries. It sells products in more than 100 markets. It has over 10,000 employees from 21 different nationalities. It focuses on making safe and high-quality medicines. It wants to improve healthcare around the world. It aims to make good medicines available to more people. 

The Indian pharmaceutical industry is one of the largest in the world. It provides affordable and high-quality medicines globally. India is known as the “Pharmacy of the World.” It supplies 50% of global vaccine demand. It also meets 40% of generic medicine needs in the U.S. and 25% in the U.K. Indian medicines are exported to more than 200 countries. The country has over 10,500 pharmaceutical manufacturing units. It also has the most U.S. FDA-approved plants outside the U.S. India plays a key role in life-saving drug production. It supplies over 80% of global antiretroviral drugs for HIV/AIDS. Indian medicines are low-cost yet high in quality. Drug manufacturing costs in India are 30-35% lower than in the U.S. and Europe. Research and development (R&D) costs are 87% lower than in developed markets. This makes Indian pharma highly competitive worldwide. The industry is growing fast. It was valued at $50 billion in 2023. It is expected to reach $130 billion by 2030. By 2047, it could touch $450 billion. Growth is driven by strong exports and rising domestic demand. The sector includes generic drugs, vaccines, biosimilars, and biologics. 

The government supports the pharma sector. The Production Linked Incentive (PLI) scheme, worth $2.04 billion, boosts local manufacturing. More funds help MSMEs and pharma clusters improve productivity. The government plans to open 10,500 Pradhan Mantri Bhartiya Jan Aushadhi Kendras by 2025. These stores provide affordable medicines to people. 

Foreign investment in pharma is increasing. India allows 100% FDI in Greenfield pharma projects. Up to 74% FDI is allowed in Brownfield projects through the automatic route. The sector has received $22.52 billion in FDI since 2000. This shows India’s strong position in the global market. The biotechnology sector is expanding. It was valued at $137 billion in 2022. It is expected to grow to $300 billion by 2030. India is among the top 12 biotechnology hubs in the world. The biosimilars market is growing at a 22% annual rate. It could reach $12 billion by 2025. The medical devices industry is also growing. It is valued at $11 billion today. By 2030, it could grow to $50 billion. The government has allocated $120 million in the 2024-25 budget for bulk drug parks. This will boost domestic production. The pharma industry is a key part of India’s economy. It contributes 1.72% to the country’s GDP. It provides jobs to millions of people. Scientists, engineers, and researchers help the industry grow. With strong investments and policies, the Indian pharma sector will expand further. It will continue to improve global healthcare in the coming years. The company is a strong player in the pharmaceutical industry. It makes high-quality medicines at low prices. It sells its products in many countries, including the U.S. and Europe. This helps it grow in global markets. 

Latest Stock News: 

On March 21, 2025, Piramal Pharma Ltd. informed BSE and NSE about the results of the e-voting process related to a postal ballot for the approval of the appointment of Ms. Nathalie Leitch as a Non-Executive, Non-Independent Director of the company. 

The company had issued a notice on February 19, 2025, regarding the remote e-voting process, where members of the company could cast their votes online from February 20, 2025, to March 21, 2025. The resolution was passed with a majority of members voting in favor of the proposal. A total of 1,797 members participated in the e-voting, with 92.21% voting in favor of the resolution and 5.79% voting against it. 

The scrutinizer’s report, which includes the details of the voting process and the final results, was also shared with the company. Based on this scrutiny, the resolution was certified as passed with the requisite majority. The report confirms that the resolution is deemed to be approved as of the last date of voting, March 21, 2025. The company has now made the results and scrutinizer’s report available on its website and on the NSDL platform for public access. 

These developments, along with the positive financial outlook and strategic initiatives discussed earlier, indicate continued confidence in Piramal Pharma’s growth trajectory and leadership decisions, which could influence investor sentiment and share price positively. 

Potentials: 

Piramal Pharma Solutions is expanding its injectables facility in Lexington, Kentucky. The company is investing $80 million for this project. The goal is to more than double the production capacity. Currently, the site produces 104 product batches per year. After expansion, this will increase to over 240 batches. The project is expected to be completed by early 2027. The investment will come from bank loans and internal funds. The expansion will add 24,000 square feet of space. A new laboratory and advanced machinery will also be added. This will help Piramal meet the rising demand for injectable medicines. The injectables market is growing fast. It is expected to reach over $20 billion by 2028. Piramal wants to become a key player in this market. The company has big goals for the future. It plans to double its revenue to $2 billion by 2030. Currently, contract manufacturing brings 58% of its revenue. The company aims to grow this segment even more. Piramal may also benefit from the US Biosecure Act. If passed, this law will stop US agencies from buying biotech equipment from certain Chinese companies. This could create more opportunities for Indian pharma companies. Piramal has already seen more business inquiries since March 2024. Other Indian pharma companies are also expanding. Zydus is increasing research for better medicines. Sun Pharma is working on drugs for obesity and diabetes. Many Indian companies are upgrading their factories to meet global standards. They are also partnering with international firms to expand worldwide. These efforts will help Indian pharma grow and provide better medicines globally. 

Analyst Insights: 

  • Market capitalisation:₹ 28,881 Cr. 
  • Current Price:₹ 218 
  • 52-Week High/Low: ₹ 308 / 119 
  • Stock P/E: 550 
  • Dividend Yield: 0.05%
  • Return on Capital Employed (ROCE): 5.49% 

Piramal Pharma’s stock is trading at ₹218 with a P/E ratio of 550.21, which is extremely high, indicating potential overvaluation. The company’s return on equity (ROE) is very low at just 0.22%, highlighting poor profit generation relative to its equity. Despite having a market cap of ₹28,881 crore, Piramal Pharma’s debt stands at ₹4,710 crore, indicating financial leverage that could be risky. The operating profit margin (OPM) has fluctuated significantly, with a dip to 5.09% in December 2022, showing inconsistent performance. On the positive side, 84% of revenues come from regulated markets like the US, Europe, and Japan, and the company’s customer base has grown to about 500, with a focus on integrated projects that accounted for 40% of new orders in FY24. While the stock’s current valuation and financial metrics raise concerns, its growth prospects in international markets and continued focus on service expansion suggest that investors should hold the stock and monitor future performance for potential improvements. 

IndusInd Bank Ltd
Why IndusInd Bank Shares Crashed 25%: The Big Discrepancy Explained Using 5Ws & 1H

Business and Industry Overview: 

IndusInd Bank is a well-known bank in India. It helps 42 million people with their money and provides banking services to individuals, businesses, and government offices. The bank has 3,063 branches and 2,993 ATMs in many cities and towns and serves people in 1,60,000 villages. No matter where people live, the bank ensures they can access banking. It even has offices in London, Dubai, and Abu Dhabi to help customers outside India. People can open savings accounts to keep their money safe, as well as current accounts for daily business needs. The bank offers loans for homes, cars, and businesses. It also provides credit cards, making shopping and payments easier. Businesses use banks to send and receive money. The bank helps small shop owners and poor people by giving small loans, allowing them to start or grow their businesses. Big companies also use the bank for trade, investments, and financial services. 

IndusInd Bank offers online banking and mobile payments. Customers can transfer money and pay bills from their phones, making banking easy, fast, and accessible. The bank was started in 1994 by Srichand P. Hinduja and other business leaders. The name comes from the Indus Valley Civilisation, which was famous for trade and business. The bank follows the same values of growth, trust, and smart money management. It has grown significantly over the years and continues to improve. The bank’s goal is to be a trusted financial partner. It focuses on good service, easy banking, and customer satisfaction. It works hard to bring banking to villages and small businesses. It ensures fair opportunities for employees and customers. The bank faces challenges as well. Many people now use online banks and mobile payment apps. This creates competition. The economy also changes, affecting how people use money. To stay strong, the bank is improving services, launching new products, and focusing on customer needs. 

IndusInd Bank wants to make banking safe, simple, and quick. It wants to help people manage their money without trouble. The bank is always growing, learning, and working hard. It aims to become one of the best banks in India. Banks keep money safe, give loans, and help people send and receive money. The Reserve Bank of India (RBI) makes rules so that banks work well. There are different banks in India. Foreign banks come from other countries. Private banks focus on good service and new technology. Government banks help many people and businesses. Rural banks give money to farmers and small shop owners. India’s FinTech market is now US$ 111 billion and may grow to US$ 421 billion by 2029. More people now pay online instead of using cash. By 2026, 65% of payments in India may be online. Banks use new technology to make things easy. Farmers can apply for Kisan Credit Card (KCC) loans online to get money fast. In September 2023, India got its first UPI-ATM, where people can take out cash without a card. By July 2024, 602 banks used UPI, and people made 15.08 billion online payments worth US$ 25.27 billion. The RBI is making a digital currency (CBDC) for quicker payments. The government is making KYC rules easy, so opening a bank account takes less time. In March 2023, India Post Payments Bank and Airtel started WhatsApp banking, so people can use their phones for banking. The banking system is growing but has some problems. Online fraud is increasing, so banks need better safety. New FinTech companies are giving more choices, so banks must work better. More people now like digital banking. The government is helping with new rules and technology. Banking in India will keep getting better. 

Latest Stock News: 

IndusInd Bank’s stock dropped sharply on March 11, 2025, falling 25.9% to an intraday low of ₹667 per share, its lowest since November 2020. The stock later recovered slightly but was still down 25.2% at 12:45 PM. This happened due to a ₹2,100 crore (pre-tax) loss found in the bank’s derivative portfolio, which led to multiple downgrades by analysts. The issue arose because the bank had not properly recorded losses from forex derivatives and swap transactions done over the past 5-7 years. However, it had included related treasury gains in its profit and loss statement. The Reserve Bank of India (RBI) had already banned such internal trades from April 1, 2024. The estimated loss of ₹1,580 crore after tax will reduce the bank’s net worth by 2.35%. Along with accelerated provisions on microfinance (MFI) loans, this will push the bank into a loss for the January- March 2025 quarter (Q4FY25). Analysts at Nuvama Institutional Equities downgraded the stock to ‘Reduce’ from ‘Hol,’ cutting the price target to from₹1,115. Emkay Global Financial Services cut its target to ₹875 from ₹1,125, while Kotak Institutional Equities reduced it to from₹1,400 and lowered expected FY25 earnings by 25%. Motilal Oswal downgraded the stock to ‘Neutral’ with a target of ₹925. The bank has appointed an external auditor to verify the actual impact, and the RBI is aware of the issue. Investors are also concerned about higher MFI stress and credit costs, which the management expects to improve in Q1FY26, while analysts believe normalization will happen by Q2FY26. The bank’s board is now looking for a new CEO, as the current CEO, Sumant Kathpalia, was given only a one-year extension instead of three. Experts believe these ongoing issues will affect investor trust and stock performance shortly. 

Potentials: 

IndusInd Bank wants to grow more in the future. India’s economy is getting better, and the country’s income (GDP) will grow more than 6%, which was the average for the last ten years. The government’s 2024-25 budget will help by building roads, railways, and other big projects. This will make the country stronger and create more jobs. The government is also helping farmers and villages so people can buy more things. Big companies will invest more money, which will help businesses grow. The bank is also getting ready for new tax rules and business laws, which will be important later. 

But some problems can slow things down. Wars between countries, very bad weather, and changes in money markets can make things harder. India also has trade problems with China, which can affect business. But India has a lot of money saved, a strong system, and flexible money rules, which will help in bad times. IndusInd Bank will keep growing, improve its services, and stay strong even if problems come. 

Analyst Insights: 

  • Market capitalisation: ₹ 51,102 Cr. 
  • Current Price: ₹ 656 
  • 52-Week High/Low:₹ 1,576 / 650 
  • Stock P/E  :7.08 
  • Dividend Yield: 2.52 % 
  • Return on Capital Employed (ROCE): 34.6 % 
  • Return on Equity: 15.2 % 

IndusInd Bank is undervalued with a P/E of 7.08, significantly lower than peers like ICICI (17.82) and HDFC (18.58). It boasts a high ROCE of 34.6%, strong revenue growth (₹11,572 Cr → ₹12,801 Cr YoY), and leadership in microfinance with 13 Mn+ customers. However, net profit declined by 39% YoY, promoter pledging is high (50.9%), and the stock has fallen 42% in a year, signaling short-term weakness. Given its strong fundamentals but near-term risks, long-term investors can buy the stock, while short-term traders should avoid it. 

Bharti Airtel
Bharti Airtel Q3 FY25 Results: Strong Net Profit Jumps 121% to ₹5,514 Cr, Revenue at ₹45,129 Cr, ARPU ₹245

Bharti Airtel Ltd: Overview 

Bharti Airtel Ltd. is one of India’s leading telecommunications service providers, with a robust presence in over 18 countries across South Asia and Africa. Established in 1995, the company has evolved into a diversified telecom player offering services that include mobile voice and data, broadband, fixed-line services, enterprise solutions, digital television, and financial services. Airtel has been at the forefront of India’s digital transformation, playing a pivotal role in expanding high-speed internet connectivity across urban and rural markets. The company operates one of the largest 4G and 5G networks in India, ensuring seamless connectivity for millions of users. Airtel’s business model is driven by a strong customer-first approach, supported by continuous investments in network expansion, digital innovations, and content partnerships. With a subscriber base of over 500 million, Airtel remains a formidable competitor in India’s telecom landscape. The Indian telecommunications industry is undergoing a rapid transformation, driven by technological advancements, increasing smartphone penetration, and the growing demand for high-speed data services. India has emerged as one of the world’s largest and fastest-growing telecom markets, with over 1.2 billion mobile subscribers and significant investments in next-generation technologies. The introduction of 5G services is set to redefine the telecom landscape, with Airtel leading the way in deployment. The government’s push for Digital India, coupled with initiatives like BharatNet, aims to improve broadband connectivity in rural areas, creating new opportunities for telecom operators. 

Latest Stock News 

As of December 31, 2024, the overall customer base stood at approximately 577 million across 15 countries, reflecting a year-on-year (YoY) growth of 4.7% compared to 551 million in the corresponding quarter last year. The company’s consolidated mobile data traffic surged by 24.2%, reaching 20,689 petabytes (PBs) during the quarter, compared to 16,656 PBs in the previous year. Total minutes of usage on the network grew by 6.8% to 1,385 billion, up from 1,297 billion in the same quarter last year. The smartphone customer base expanded to 270.2 million, recording an increase of 6.5 million quarter-on-quarter (QoQ) and 25.2 million YoY. The company’s capital expenditure for the quarter amounted to ₹91,608 million. In the Digital TV Services segment, the average revenue per user (ARPU) for the quarter stood at ₹160, slightly higher than ₹158 in the previous quarter, with net customer additions of 29,000. The Homes segment continued its expansion, with operations spanning 1,427 cities (including Local Cable Operators), witnessing a robust revenue growth of 18.7% YoY. Net customer additions in this segment totalled approximately 674,000 during the quarter, bringing the overall customer base to 9.2 million. 

Business Segments 

  • Mobile Services (India & South Asia): Airtel is the second-largest telecom operator in India, offering 2G, 4G, and 5G services to millions of customers. The company has a strong focus on ARPU (Average Revenue Per User) growth, driven by premiumization strategies such as higher 4G and 5G adoption, post-paid plan expansion, and bundled content services. Airtel’s “Airtel Black” strategy, which provides bundled mobile, broadband, and DTH services, has seen strong traction. 
  • Airtel Business (Enterprise Solutions): Airtel Business is one of India’s largest B2B telecom service providers, catering to corporates, government institutions, and small businesses. The segment offers cloud computing, cybersecurity, data center solutions, IoT connectivity, and managed services. Airtel has partnered with global technology firms like Google Cloud, AWS (Amazon Web Services), and Cisco to strengthen its enterprise offerings. 
  • Home Broadband & DTH Services: Airtel’s broadband segment has grown significantly under Airtel Xstream Fiber, offering high-speed fiber-optic internet across 1,200+ cities in India. The company has aggressively expanded its fiber network, targeting 40 million homes by 2025. With a focus on Wi-Fi 6 routers, mesh networking, and OTT content bundles, Airtel is enhancing user experience and driving customer retention. The DTH (Direct-to-Home) segment, offered through Airtel Digital TV, provides digital television services to millions of Indian households. 
  • Payments & Financial Services: Airtel operates Airtel Payments Bank, India’s first payments bank, which provides financial inclusion solutions such as digital wallets, UPI transactions, and micro-loans. The bank has witnessed strong growth, driven by an increasing number of digital transactions and rural banking initiatives. Airtel has also partnered with financial institutions to offer insurance, credit, and investment products through its digital platform. 

Subsidiary Information 

  • Airtel Africa: Airtel Africa is a major player in the African telecom market, operating in 14 countries, including Nigeria, Kenya, Uganda, and Tanzania. The subsidiary offers mobile voice, data, and financial services, catering to over 140 million customers. The company has been expanding mobile money services under Airtel Money, driving financial inclusion in underserved regions. 
  • Nxtra by Airtel: Nxtra by Airtel is the company’s data center subsidiary, providing cloud computing and colocation services. As India’s demand for data storage, AI-driven analytics, and cybersecurity solutions increases, Nxtra is expanding its green data centers across multiple locations. Airtel has committed significant investments in energy-efficient and AI-powered infrastructure, ensuring compliance with global data security standards. 
  • Airtel Payments Bank: Airtel Payments Bank operates as a financial inclusion initiative, offering digital wallets, micro-insurance, and payment solutions. The bank has a vast rural and urban customer base, benefiting from Airtel’s extensive network coverage. The increasing shift towards cashless transactions and government-backed financial inclusion programs makes Airtel Payments Bank a high-potential subsidiary. 

Q3 FY25 Earnings 

  • Revenue of ₹45129 crore in Q3 FY25 up by 19.08% YoY from ₹37900 crore in Q3 FY24.  
  • EBITDA of ₹24597 crore in this quarter at a margin of 54% compared to 52% in Q3 FY24. 
  • Profit of ₹16135 crore in this quarter compared to a ₹2876 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 37900 45129 139145 149982 
Expenses 18085 20533 67871 71691 
EBITDA 19815 24597 71274 78292 
OPM 52% 54% 51% 52% 
Other Income 1013 9675 1019 -3428 
Net Profit 2876 16135 12287 8558 
NPM 7.5% 35.7% 8.8% 5.7% 
EPS 4.3 25.9 14.9 13.2